---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-016039"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2022-08-09T23:59:59+00:00"
generated_at: "2026-06-24T02:04:56.813832+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q2 revenue $30M (+45% YoY); raises FY22 guidance to $130-134M; net loss widens to $17.2M

## Summary
- Revenue $30M, +45% YoY; gross margin 81.1% (+20 bps). Direct channel 68% of sales vs 51% prior year.
- Net loss attributable to common $17.2M ($0.31/share) vs $5.1M loss prior year; adjusted net loss $12.8M ($0.23/share).
- Adjusted EBITDA loss $9.4M vs $3.1M loss prior year; operating expenses increased to $36.2M from $20.7M.
- Raises FY2022 revenue guidance to $130-134M (38-42% growth) from prior $128-133M.
- Ended Q2 with $101.5M cash; new $150M loan arrangement provides liquidity.

## SEC filing metadata
- accession: 0000950170-22-016039
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2022-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017022016039/0000950170-22-016039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017022016039/tmci-20220809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-016039
- JSON: https://secwatch.observer/filing/0000950170-22-016039.json
- Plain text: https://secwatch.observer/filing/0000950170-22-016039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.